CA
NZ
UK
AU
IND
US
…
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Tscan Therapeutics develops T-cell receptor (TCR) engineered cell therapies and a TCR-discovery platform to identify tumor-specific receptors for oncology applications. Long-term growth drivers include clinical-stage progress of its pipeline, validation and licensing of its discovery technology, and broader adoption of TCR-based adoptive cell therapies which may benefit from advances in immuno-oncology and manufacturing.
Material risks include high clinical and execution risk as an early-stage company with no approved products, ongoing cash burn and likely future financing needs, manufacturing complexity, and intense competition from CAR-T and other immunotherapy approaches.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -66.22M | -48.62M | -26.13M | -13.66M |
| Net income | -65.81M | -48.62M | -26.02M | -13.11M |
| Selling general administrative | 20.35M | 13.83M | 6.74M | 4.77M |
| Gross profit | 13.54M | 10.14M | 1.08M | - |
| Reconciled depreciation | 5.14M | 3.33M | 1.23M | 0.52M |
| Ebit | -66.64M | -48.64M | -26.23M | -14.21M |
| Ebitda | -65.05M | -45.31M | -25.00M | -13.69M |
| Depreciation and amortization | 1.59M | 3.33M | 1.23M | 0.52M |
| Non operating income net other | 0.41M | - | - | - |
| Operating income | -66.64M | -48.64M | -26.23M | -14.21M |
| Other operating expenses | 80.17M | 58.78M | 27.32M | 14.21M |
| Interest expense | 1.18M | 0.02M | 0.00M | 0.00M |
| Interest income | 1.59M | - | 0.11M | 0.55M |
| Net interest income | 0.41M | 0.02M | 0.11M | 0.55M |
| Income tax expense | -0.41M | -0.02M | -0.11M | -0.55M |
| Total revenue | 13.54M | 10.14M | 1.08M | 0.00M |
| Total operating expenses | 80.17M | 58.78M | 27.32M | 14.21M |
| Total other income expense net | 0.41M | 0.02M | 0.11M | 0.55M |
| Net income from continuing ops | -66.22M | -48.64M | -26.13M | -13.66M |
| Net income applicable to common shares | -66.22M | -48.62M | -26.13M | -13.66M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 272.15M | 199.09M | 188.11M | 49.74M | 49.38M |
| Other current assets | 2.19M | 4.10M | 4.25M | 1.65M | 0.61M |
| Total liab | 121.28M | 99.66M | 27.33M | 92.20M | 66.52M |
| Total stockholder equity | 150.87M | 99.43M | 160.78M | -42.46M | -17.14M |
| Other current liab | 10.72M | 6.84M | 6.52M | 2.49M | 0.03M |
| Common stock | 0.01M | 0.00M | 0.00M | 0.00M | - |
| Capital stock | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -247.60M | -158.38M | -92.16M | -43.53M | -17.41M |
| Other liab | - | 0.05M | 1.59M | 9.05M | - |
| Other assets | - | 5.76M | 5.20M | 0.76M | 0.59M |
| Cash | 133.36M | 120.03M | 161.41M | 34.79M | 41.76M |
| Total current liabilities | 29.82M | 17.30M | 21.34M | 17.45M | 2.40M |
| Current deferred revenue | 10.14M | 3.87M | 11.41M | 10.63M | 0.91M |
| Net debt | -40.93M | -34.04M | -155.36M | -27.36M | -36.88M |
| Short term debt | 6.59M | 3.68M | 1.65M | 1.42M | 0.44M |
| Short long term debt | 3.35M | - | - | - | - |
| Short long term debt total | 92.43M | 85.98M | 6.04M | 7.43M | 4.89M |
| Other stockholder equity | 398.46M | 257.81M | 252.93M | 1.07M | 0.27M |
| Property plant equipment | - | 10.10M | 11.77M | 12.53M | 6.41M |
| Total current assets | 194.24M | 120.03M | 165.65M | 36.45M | 42.38M |
| Net tangible assets | - | 99.43M | 160.78M | -42.46M | -17.14M |
| Short term investments | 58.69M | - | - | - | - |
| Long term debt | 26.70M | 29.29M | - | - | - |
| Accounts payable | 2.37M | 2.91M | 1.76M | 2.91M | 1.01M |
| Accumulated other comprehensive income | - | - | -188.11M | - | - |
| Common stock total equity | - | 0.00M | 0.00M | 0.00M | 0.03M |
| Retained earnings total equity | - | -158.38M | -92.16M | - | - |
| Non currrent assets other | 1.65M | 9.86M | 5.20M | 0.76M | 0.59M |
| Non current assets total | 77.91M | 79.06M | 22.45M | 13.29M | 7.00M |
| Capital lease obligations | 62.39M | 56.69M | 6.04M | 7.43M | 4.89M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -4.22M | -9.94M | -4.24M | -1.25M |
| Change to liabilities | 1.26M | 3.24M | 20.57M | 0.16M |
| Total cashflows from investing activities | -4.22M | -9.94M | -4.24M | -1.25M |
| Net borrowings | 29.03M | 29.35M | 29.35M | 29.35M |
| Total cash from financing activities | 29.36M | 189.67M | 0.29M | 34.81M |
| Change to operating activities | -1.73M | 0.63M | 0.79M | 0.14M |
| Net income | -66.22M | -48.62M | -26.13M | -13.66M |
| Change in cash | -41.37M | 131.05M | -6.97M | 21.04M |
| Begin period cash flow | 166.44M | 35.39M | 42.36M | 21.32M |
| End period cash flow | 125.06M | 166.44M | 35.39M | 42.36M |
| Total cash from operating activities | -66.50M | -48.68M | -3.02M | -12.52M |
| Issuance of capital stock | 0.19M | 189.38M | 0.00M | 34.81M |
| Depreciation | 5.14M | 3.33M | 1.23M | 0.52M |
| Sale purchase of stock | 0.33M | 189.67M | - | - |
| Other cashflows from financing activities | 29.49M | 100.02M | -4.24M | -1.25M |
| Change to netincome | 4.55M | 2.52M | 0.52M | 0.32M |
| Capital expenditures | 4.22M | 9.94M | 4.24M | 1.25M |
| Cash flows other operating | -11.23M | -9.14M | - | - |
| Cash and cash equivalents changes | -41.37M | 131.05M | - | - |
| Change in working capital | -10.23M | -5.90M | 21.36M | 0.30M |
| Stock based compensation | 4.55M | 2.52M | 0.52M | 0.24M |
| Other non cash items | 0.26M | -125.36M | 0.00M | 0.08M |
| Free cash flow | -70.73M | -58.62M | -7.26M | -13.77M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TCRX Tscan Therapeutics Inc |
0.00 1.76% |
0.19 | - | - | 17.64 | 2.48 | 13.02 | -3.42 |
| NVO Novo Nordisk A/S |
1.03 2.56% |
41.34 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.49 0.27% |
548.58 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
18.16 2.01% |
922.51 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. David P. Southwell | Pres, CEO & Director | 1961 |
| Mr. Brian Michael Silver J.D. | Sr. VP, CFO & Treasurer | 1969 |
| Dr. Gavin MacBeath Ph.D. | Chief Scientific & Operations Officer | 1970 |
| Dr. Stephen J. Elledge Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | NA |
| Mr. Tomasz Kula Ph.D. | Co-Founder & Member of Advisory Board | NA |
| Mr. Ray Lockard | VP of Technical Operations & Quality | NA |
| Ms. Heather Savelle | VP of Investor Relations | NA |
| Dr. Zoran Zdraveski J.D., Ph.D. | Chief Legal Officer & Company Sec. | 1970 |
| Ms. Ann Hargraves | VP of HR | NA |
| Dr. William Desmarais M.B.A., Ph.D. | Chief Bus. Officer | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.73%
Communication Services
+0.67%
Consumer Cyclical
+1.27%
Consumer Defensive
+0.61%
Energy
+0.65%
Financial Services
+0.96%
Financials
+0.55%
Healthcare
+1.48%
Industrials
+1.64%
Real Estate
+0.54%
Technology
+2.26%
Utilities
+0.63%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-5.20%
Please wait processing your request...